Nona Biosciences, a company involved in technology innovation and antibody discovery and development services, entered into a strategic collaboration with GeneQuantum Healthcare to advance the early discovery of next generation bioconjugates.

Nona Biosciences will integrate GeneQuantum’s iLDC (intelligent Ligase-dependent Conjugation) and iGDC (intelligent Glycotransferase-dependent conjugation) platforms, with Nona Biosciences’ Harbor Mice platform and  technologies, to further enhance technology platform capabilities, providing services for the early discovery of next-generation bioconjugates.

“Leveraging our cutting-edge antibody technologies and extensive experience in antibody research and development, Nona is committed to providing innovative, diverse and customized solutions for preclinical drug development,” said Jingsong Wang, chairman of Nona Biosciences. “These efforts have garnered widespread recognition and appreciation from our partners. We look forward to collaborating with GeneQuantum Healthcare to continuously enhance the capabilities of innovative bioconjugate drug research and development, empowering global partners to advance their ADC drug R&D initiatives.”

“Through years of interdisciplinary and differentiated innovation, GeneQuantum has developed iLDC and iGDC platforms as the core technology for bioconjugate drugs, offering a comprehensive solution for ADC drug R&D and manufacture,” said Gang Qin, founder, and chairman of GeneQuantum Healthcare. “Overcoming the challenges prevalent in the current ADC field, such as heterogeneity, poor stability, process complexity, difficulty in scale-up manufacture, these leading technologies significantly reduce the production cost, improve the drug quality, and increase the ADC drug global accessibility.”